---
title: Digital Adherence Program_Valdoxan
description: General education and support on treatment knowledge, medication use, and precautions for use, adverse effects and interactions with other medicines.
---

[![ma_logo_horizontal_full_white_bg](https://www.mymedadvisor.com/hubfs/ma_logo_horizontal_full_white_bg.svg "ma_logo_horizontal_full_white_bg")](http://mymedadvisor.com)

# Valdoxan**® **(**agomelatine**)

Digital Adherence Program

Program overview

This sponsored program aims to provide education and support to patients prescribed Valdoxan for the treatment of depression and/or anxiety.

Patients will receive a series of 12 messages over 9 months aimed at improving their quality use of medicines, medication adherence and treatment outcomes.

When?

This program was launched in December 2021.

For which patients?

Messages will be delivered via the app and SMS to patients currently prescribed Valdoxan. 

[Click here to view a sample of the messages](https://www.mymedadvisor.com/hubfs/VALDOXAN_DAP%20messages-1.pdf?hsLang=en)

![Valdoxan-1](https://www.mymedadvisor.com/hs-fs/hubfs/Valdoxan-1.png?width=253&name=Valdoxan-1.png "Valdoxan-1")

© 2026 MedAdvisor International Pty Ltd